ATE444083T1 - Selektives targeting von apoptotischen zellen - Google Patents

Selektives targeting von apoptotischen zellen

Info

Publication number
ATE444083T1
ATE444083T1 AT02774165T AT02774165T ATE444083T1 AT E444083 T1 ATE444083 T1 AT E444083T1 AT 02774165 T AT02774165 T AT 02774165T AT 02774165 T AT02774165 T AT 02774165T AT E444083 T1 ATE444083 T1 AT E444083T1
Authority
AT
Austria
Prior art keywords
apoptotic cells
selective target
agent
vertebrate
arsenoxide
Prior art date
Application number
AT02774165T
Other languages
English (en)
Inventor
Philip Hogg
Original Assignee
Newsouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newsouth Innovations Pty Ltd filed Critical Newsouth Innovations Pty Ltd
Application granted granted Critical
Publication of ATE444083T1 publication Critical patent/ATE444083T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
AT02774165T 2001-11-08 2002-11-08 Selektives targeting von apoptotischen zellen ATE444083T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8746A AUPR874601A0 (en) 2001-11-08 2001-11-08 Selective targeting of apoptotic cells
PCT/AU2002/001523 WO2003039564A1 (en) 2001-11-08 2002-11-08 Selective targeting of apoptotic cells

Publications (1)

Publication Number Publication Date
ATE444083T1 true ATE444083T1 (de) 2009-10-15

Family

ID=3832565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774165T ATE444083T1 (de) 2001-11-08 2002-11-08 Selektives targeting von apoptotischen zellen

Country Status (10)

Country Link
US (2) US7635464B2 (de)
EP (1) EP1453525B1 (de)
JP (2) JP2005511598A (de)
AT (1) ATE444083T1 (de)
AU (2) AUPR874601A0 (de)
CA (1) CA2466303A1 (de)
DE (1) DE60233891D1 (de)
ES (1) ES2330203T3 (de)
WO (1) WO2003039564A1 (de)
ZA (1) ZA200403803B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ296799A0 (en) * 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
JP4426456B2 (ja) 2002-11-07 2010-03-03 ニューサウス イノベイションズ ピーティーワイ リミテッド ミトコンドリア膜透過性遷移の誘導
US7264794B2 (en) * 2004-12-17 2007-09-04 The General Hospital Methods of in vivo cytometry
US7491502B2 (en) * 2004-12-17 2009-02-17 The General Hospital Corporation In vivo flow cytometry system and method
CA2599709A1 (en) 2005-03-09 2006-09-21 Cepheid Polar dyes
WO2008052279A1 (en) * 2006-11-01 2008-05-08 Newsouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof
US7776999B2 (en) 2007-04-12 2010-08-17 Battelle Memorial Institute Cyanine-based probe\tag-peptide pair for fluorescence protein imaging and fluorescence protein imaging methods
US20110060232A1 (en) * 2007-05-04 2011-03-10 The General Hospital Corporation Retinal flow cytometry
WO2009043114A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Arsenoxide compound and method of use
US8574859B2 (en) 2008-03-27 2013-11-05 The General Hospital Corporation In vivo flow cytometry based on cellular autofluorescence
KR101077618B1 (ko) * 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
WO2016061618A1 (en) * 2014-10-24 2016-04-28 Newsouth Innovations Pty Limited Selective targeting of procoagulant platelets
CA2975406C (en) * 2015-02-01 2025-07-22 Quetzal Therapeutics, Llc LYOPHILIZED COMPOSITIONS WITH HIGH SPECIFIC SURFACE AREA CONTAINING ARSENIC INTENDED FOR ORAL ADMINISTRATION IN PATIENTS
US20220152229A1 (en) * 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents
US12544929B2 (en) 2021-07-21 2026-02-10 Mujin, Inc. Robotic system with depth-based processing mechanism and methods for operating the same
CN115570556B (zh) * 2021-07-21 2025-06-17 牧今科技 具有基于深度的处理机制的机器人系统及其操作方法
CN117756125A (zh) * 2023-12-22 2024-03-26 广西大学 一种超细纳米硅酸钙纤维及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883659A (en) 1973-05-18 1975-05-13 Ciba Geigy Corp 9-Oxaprostaglandin compositions
EP0981344A1 (de) 1997-05-14 2000-03-01 The University of New Mexico Hemmung der disulfid isomerase der zellwand
EP1391206B1 (de) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von nicht-Hodgkihn-Lymphome
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
FR2781674B1 (fr) * 1998-07-31 2002-06-28 Inst Nat Sante Rech Med Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
US6191123B1 (en) * 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR598901A0 (en) * 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
JP4426456B2 (ja) * 2002-11-07 2010-03-03 ニューサウス イノベイションズ ピーティーワイ リミテッド ミトコンドリア膜透過性遷移の誘導

Also Published As

Publication number Publication date
CA2466303A1 (en) 2003-05-15
US20050101524A1 (en) 2005-05-12
DE60233891D1 (de) 2009-11-12
ZA200403803B (en) 2006-03-29
AUPR874601A0 (en) 2001-11-29
JP2011006467A (ja) 2011-01-13
EP1453525B1 (de) 2009-09-30
EP1453525A1 (de) 2004-09-08
AU2002340631B2 (en) 2006-08-10
EP1453525A4 (de) 2006-03-15
JP2005511598A (ja) 2005-04-28
ES2330203T3 (es) 2009-12-07
US7635464B2 (en) 2009-12-22
US20090311179A1 (en) 2009-12-17
WO2003039564A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
DE60233891D1 (de) Selektives targeting von apoptotischen zellen
WO2004064769A3 (en) Methods for making and using topical delivery agents
DK1265889T3 (da) Lægemidler imod virussygdomme
CR7171A (es) Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados
ATE376587T1 (de) Granulat mit hoher schlagfestigkeit
EP1411118A4 (de) Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
UY27346A1 (es) Composiciones farmaccuticas que contienen conjuntos de polemero y frrmaco.
DE60334678D1 (de) Antikörper enthaltende pharmazeutische lösungen
BR0215405A (pt) Composições e processos de uso de collajolie
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
WO2002000167A3 (en) Modified forms of pharmacologically active agents and uses therefor
WO2004045572A8 (en) Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
DK1492506T3 (da) Matrix for depot-, invariant- og uafhængig-frigörelse af aktive forbindelser
WO2005042560A3 (en) Non-viral delivery of compounds to mitochondria
SE0101932D0 (sv) Pharmaceutical combinations
EP1319402A4 (de) IgE-ENTSTEHUNGSHEMMSTOFFE
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
ITTO20010321A0 (it) Procedimento per la trasmissione di messaggi sms con identita' protetta.
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
BR0212227B1 (pt) Agente e processos para desbaste de frutas, bem como seu emprego
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
NL1026201A1 (nl) Heterodyne bundelafgifte met actieve sturing van twee orthogonale polarisaties.
ATE404602T1 (de) Wässrige polyurethanzubereitungen
EP2071030A3 (de) Oligoribonukleotid- und Peptidnukleinsäure zur Hemmung der Aktivität des Hepatitis-C-Virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties